Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6425
    -0.0001 (-0.01%)
     

  • OIL

    82.87
    +0.14 (+0.17%)
     

  • GOLD

    2,406.70
    +8.70 (+0.36%)
     

  • Bitcoin AUD

    100,394.63
    +1,496.62 (+1.51%)
     

  • CMC Crypto 200

    1,385.98
    +73.35 (+5.92%)
     

  • AUD/EUR

    0.6026
    -0.0005 (-0.08%)
     

  • AUD/NZD

    1.0896
    +0.0021 (+0.19%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,165.90
    -228.41 (-1.31%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,938.53
    +163.15 (+0.43%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

ChemoCentryx to Hold Second Quarter 2020 Financial Results Conference Call on Monday, August 10, 2020

ChemoCentryx, Inc.
·1-min read

MOUNTAIN VIEW, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2020 financial results will be released after market close on Monday, August 10, 2020. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 10, 2020 to discuss these results and to answer questions.

To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 6246545. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis.

ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

ADVERTISEMENT

Contacts:

Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
investor@chemocentryx.com

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

Investors:
William Slattery, Jr., Burns McClellan
212.213.0006
bslattery@burnsmc.com